<DOC>
	<DOCNO>NCT02034747</DOCNO>
	<brief_summary>This study multicenter , randomize , comparison , open-label , phase IV study kidney transplant recipient whose immunosuppressive regimen convert Cyclosporine corticosteroid Advagraf® corticosteroid . The eligible patient randomize either Arm 1 Arm 2 . The Arm 1 reduce corticosteroid slowly 50 % low dose 4 week 12 week Advagraf®-based immunosuppressive regimen , Arm 2 receive corticosteroid dose 24 week Advagraf ® .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Advagraf® Switching From Cyclosporine Between Group That Was Treated With 50 % Reduced Corticosteroid Group With Maintained Corticosteroid Stable Kidney Transplant Recipients</brief_title>
	<detailed_description>The primary objective ass change GFR 24 week treatment group reduce corticosteroid slowly 50 % low dose 4 week 12 week group maintain corticosteroid stable kidney transplant subject whose regimen convert CyA-based immunosuppressive regimen corticosteroid Advagraf®-based immunosuppressive regimen corticosteroid kidney transplant subject whose regimen convert CyA-based immunosuppressive regimen . The secondary objective ass creatinine clearance rate , acute rejection , satisfaction medication safety group 50 % reduce dose corticosteroid group Advagraf ®-based immunosuppressive regimen maintain corticosteroid .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Had kidney transplant least 12 month his/her enrollment study ( include kidney retransplantation ) . Underwent CyAbased immunosuppressive regimen since his/her last transplantation . The CyA dose remain unchanged last four week subject 's enrollment . The immunosuppressive regimen ( combination medication ) remain unchanged minimum four week subject 's enrollment . GFR≥30 mL/min Had receive organ transplant kidney Had acute rejection episode within 12 week his/her enrollment study , acute rejection episode within 24 week his/her enrollment study require antilymphocyte antibody therapy Had diagnose newonset malignancy his/her transplantation , except basocellular squamous cell carcinoma skin treat successfully The subject receive kidney transplant fullHLA identical donor Known FSGS MPGN Type II underlie disease Has elevate SGPT/ALT and/or SGOT/AST and/or total bilirubin level ≥ 2 time upper value normal range investigate site Has liver cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Advagraf</keyword>
	<keyword>kidney transplant</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Immunosuppressive regimen</keyword>
</DOC>